BARCELONA, Spain--(BUSINESS WIRE)--Veeva Systems (NYSE:VEEV) today announced the availability of Veeva Vault EDC to help clinical data management teams better run clinical trials. Veeva Vault EDC delivers a flexible, modern cloud application to easily design studies, manage amendments, and improve the speed and quality of data collection. Veeva is bringing together EDC and eSource with CTMS and eTMF to provide the industry’s first and only suite of unified cloud applications to streamline clinical operations and clinical data management.
“Veeva Vault EDC allows life sciences companies to run the trial they want, not the trial their technology limits them to,” said Brian Longo, senior vice president and general manager, Veeva Vault EDC. “With a modern cloud EDC, clinical teams can reduce cost and complexity to deliver better data faster and accelerate trial execution.”
Traditional EDC systems struggle to address the growing complexity and volume of data in clinical trials. Systems are difficult to integrate and performance is often slow as large amounts of data are collected. Study amendments require costly and time consuming data migrations and system downtime.
Veeva Vault EDC gives clinical data management teams the flexibility to design complex studies faster and easily manage amendments with no downtime or data migration. Its modern cloud architecture easily integrates with other clinical applications and scales to manage increasing volumes of data. Personalized views and prioritized tasks focus efforts on the most critical actions. Clinical trial teams can now build and execute studies with greater efficiency to speed clinical trials.
Customers can use Veeva Vault EDC as a standalone application or combine it with electronic source data capture with Vault eSource, planned for availability in December 2017. Together, Vault EDC and Vault eSource eliminate the need to transcribe patient data into an EDC system and cut costly and time-consuming source data verification by clinical monitors.
Veeva Vault EDC is available today as part of the Veeva Vault Clinical Suite, which also includes Vault eSource, Vault CTMS, Vault eTMF, Vault Study Startup, and Vault SiteExchange. The Veeva Vault Clinical Suite enables life sciences companies to seamlessly manage all content and data across clinical trials.
For more on Veeva Vault EDC, visit: veeva.com/eu/VaultEDC
For more on how to run the trial you want, visit: veeva.com/eu/BetterEDC
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @Veeva_EU on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit www.veeva.com/eu.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s filing on Form 10-Q for the period ended January 31, 2017. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.